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Background/aim: Malignant melanoma is the most common cause of death due to skin cancers. The most common mutations in RAFRAS pathway from tumor oncogenes are BRAF and NRAS. In this study, we analyzed the frequency of BRAF and NRAS gene mutations
and investigated their association with clinicopathological features of melanomas in the Turkish population.
Materials and methods: 65 primary cutaneous melanoma were included in the study. The mutations were evaluated with real-time PCRbased PCR-array through allele-specific amplification, and the results were correlated with various clinicopathological characteristics.
Results: 52.3% of the patients were female and 47.7% were male. The mean age of the patients with a mutation was lower than those
without mutation. 16 patients had BRAF mutation. 12 patients had NRAS mutation. NRAS mutation was statistically more common in
men (P = 0.036). The number of mitoses increased with the increase of the tumor thickness (P = 0.003). There was more mitosis in the
presence of ulceration (P = 0.05). A total of 41.7% of NRAS mutations had adjuvant chemotherapy.
Conclusion: We found lower mutation rate when compared to regional studies. NRAS mutation was common in men. This is the first
study from our region evaluating the prognostic value of clinical stage and necessity of adjuvant treatment with the presence of BRAF
and NRAS mutations.
Keywords: Malignant melanoma, mutation, BRAF, NRAS, real-time PCR

1. Introduction
The incidence of malignant melanoma (MM) of the skin
has steadily increased in the past decades (1). New studies
regarding the biology of melanoma and its molecular
mechanisms have led to new investigations of targeted
therapies (2).
Stem cell growth factor receptor (KIT) and mitogenactivated protein kinase (MAPK) cascade including
RAS-RAF-MEK-ERK are important pathways mediating
cellular responses to growth signals regulating cell
proliferation, survival, and differentiation (3). KIT is
a cytokine receptor that is expressed on the surface of
melanocytes. Altered forms of this receptor are associated
with some melanoma types (4). NRAS and BRAF
mutations are mainly involved in the pathogenesis of
melanoma. BRAF is a member of the RAF kinase family
of growth signal transduction protein kinases and it
takes part in regulating the MAPK pathway (5). NRAS
is a member of RAS family of GTPases and the most

commonly mutated isoform in melanoma (6). Mutations
in kinases in the MAPK signal transduction pathway
have been found about 40% – 70% of melanomas (3, 7).
The information about mutation frequencies of
melanoma from the Middle East region is limited. In
this study, we aimed to determine the frequency of both
BRAF and NRAS mutations, the correlation between
the presence of mutations and tumor depth, histological
subtypes, growth pattern, the presence of ulceration,
regression, tumor localization, and mitosis number per
mm2. Also, we evaluated the prognostic value of the
presence of mutation by evaluating the clinical stages at
diagnosis, disease-free and diseased survival periods, and
adjuvant therapies.
2. Materials and Methods
2.1. Tumor Samples
Formalin-fixed paraffin-embedded (FFPE) blocks of
patients diagnosed as MM between 2006 and 2013 were
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examined at the department of pathology, Celal Bayar
University, Manisa. A total of 81 primary cutaneous
melanoma patients with available blocks were selected.
Sixteen of the cases were excluded because of low quality
or insufficient DNA. At last 65 cases of the primary
cutaneous melanoma were included in the study. The
study was approved by the Ethics Committee of Faculty
of Medicine, Celal Bayar University, Manisa, Turkey.
Clinical information of the patients including age,
sex, and tumor localization was obtained from pathology
reports. Tumor thickness classified according to Clark
level and Breslow level, number of mitosis per square
millimeter, and ulceration, growth phase, presence
of lypmhocytic and lymphovascular infiltration, and
presence of regression were reviewed with hematoxylin
and eosin-stained sections. Cases were classified into
melanoma in situ (MIS), superficial spreading melanoma
(SSM), nodular melanoma (NM), lentigo maligna
melanoma (LMM), and acral lentiginous melanoma
(ALM) according to the current classification of World
Health Organization.
Areas containing viable tumors were marked on
the hematoxylin and eosin-stained slides, and tumor
tissue was manually dissected from 5 unstained paraffin
sections (thickness per section was 8 µm). Two samples
were prepared for each patient for both BRAF and NRAS
mutations.
2.2. Mutation analysis
2.2.1. DNA extraction
Samples of DNA were extracted from paraffin-embedded
tumor tissue via QIAamp DNA FFPE Tissue Kit (cat.
56404; Qiagen, GmbH, Hilden, Germany) according to
the manufacturer’s protocol. DNA measurements of the
purified samples were made with the NanoDrop device,
and the DNA samples with the suitable purity and
concentration levels were selected to use in BRAF and
NRAS mutation analysis.
2.2.2. Mutation Analysis of BRAF and NRAS
BRAF mutations were detected with Easy® BRAF kit
(Diatech Pharmacogenetics; cat. no. RT002) which
allows detecting the main mutations of codon 600 of
the gene BRAF using 5 oligo mixes. NRAS mutation
detections were performed with Easy® NRAS kit
(Diatech Pharmacogenetics; cat. no. RT004) which allows
detecting the main mutations of exon 2 (codons 12, 13),
exon 3 (codons 59, 61), and exon 4 (codons 117, 146) of
NRAS gene of EGFR gene using 8 oligo mixes. Each mix
allows the coamplification of one or more mutated alleles.
Related kits allow the detection of low percentages of
mutated allele in the presence of high amounts of wild
type genomic DNA by real-time amplification with
sequence-specific probes marked with FAM and HEX
(LOD down to 0.5%).
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2.3. Clinical Information
Files of patients who had mutation analysis result were
investigated. Clinical stage of the disease at the time of
diagnosis was noted. Adjuvant therapy information,
disease-free and the overall survival time, and the
duration of follow-up were recorded.
2.4. Statistical Analysis
Correlation of mutation status with clinical and
pathological features was analyzed by using Pearson X 2,
Mann–Whitney U, and one-way analyses of variance
(ANOVA) test together with the Log-logistic regression
test to calculate statistical significance. All analyses
were two tailed and the value of P < 0.05 was considered
as statistically significant. Statistical analyses were
performed by the SPSS 21.0 (Chicago, IL, USA) software.
3. Results
The clinical and pathological data are listed in Table.
A total of 34 (52.3%) of the patients were female and 31
(47.7%) were male. The ages of patients ranged between
18 and 80 (mean: 59.9). Tumor histology was melanoma
in situ (MIS) in 8 (12.3%) patients, while it was nodular
melanoma (NM) in 18 (27.7%), superficial spreading
melanoma (SSM) in 12 (18.5%), lentigo maligna melanoma
(LMM) in 19 (29.2%), and acral lentiginous melanoma
malignant (ALM) in 8 (12.3%) patients. The localization
of the tumor was head and neck in 33 (50.7%), trunk in
11 (16.9%), and extremities in 21 patients (32.3%). Tumor
thickness ranged between 0.1 and 40 mm (median, 3
mm). The mean number of mitoses per square millimeter
was 1.96 (0–13). The number of mitoses increased with
the increase of tumor thickness, and mitosis was more
common with the presence of ulceration (P = 0.003 and
P = 0.05). Four of the tumors were classified as Clark
1 (6.2%), 8 of the tumors were Clark 2 (16.3%), 8 of the
tumors were Clark 3 (16.3%), 33 of the tumors were Clark
4 (50.8%), and 12 of the tumors were Clark 5 (18.5%).
Thirty (46.1%) of the tumors had ulceration. Fifty three
(81.5%) of the tumors had no regression, 10 (15.3%) had
less than 50% regression and 2 (3%) had more than 50%
regression. Thirty-three (50.7%) of the tumors had no
lymphocytic infiltration, 9 (13.8%) of the tumors were
classified as brisk, and 23 (35.3%) of the tumors were
classified as nonbrisk. There was no significant difference
between tumor infiltrating lymphocyte grade (TIL) and
overall BRAF and NRAS mutations (P = 0.95, P = 0.56, P
= 0.48, consequently). At the time of diagnosis, 27 of the
patients were evaluated as stage 0 or 1 (41.53%), 28 patients
were stage 2 (43.07%), 8 patients were stage 3 (12.3%), and
2 patients were stage 4 (3%). There was no significant
correlation between mutation status and clinical stage
at the diagnosis. Evaluation was performed again for
metastatic and nonmetastatic diseases with mutation
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Table: Clinicopathological features of mutations and statistical analysis.
Overall mutation

BRAF

Mutation,
n (%)

Wild,
n (%)

Total

24 (36.9)

41 (63.1)

Age, yr mean

56.58

61.87

Sex
Male
Female

12 (38.7)
12 (35.3)

19 (61.3)
22 (64.7)

Breslow mm
≤1
1.01-2.0
2.01-4.0
> 4.0

10
3
3
8

11
5
11
14

Ulceration
Present
Absent

13 (54.2)
11 (45.8)

16 (39)
25 (61)

Regression
Absent
<50%
>50%

19 (79.2)
4 (16.8)
1 (4.2)

34 (83.0)
6 (14.6)
1 (2.4)

Growth Phase
Radial
Vertical
Radial + Vertical

7 (53.8)
4 (23.5)
13 (37.1)

6 (46.2)
13 (76.5)
22 (63.9)

Mitosis

1.66

2.14

Localization
Head&Neck
Trunk
Extremity

10 (30.3)
3 (27.3)
11 (52.4)

23 (69.7)
8 (72.7)
10 (47.6)

Subtypes
MIS
NM
SSM
LMM
ALM

3
5
5
6
5

(37.5)
(27.8)
(41.7)
(31,6)
(62.5)

5
13
7
13
3

(62.5)
(72.2)
(58.3)
(68.4)
(37.5)

Stage at the diagnoses
Stage 1
Stage 2
Stage 3
Stage 4

13
7
4
0

(48.1)
(25)
(50)
(0)

14
21
4
2

(51.9)
(75)
(50)
(100)

Adjuvant therapy
None
CT
CT + RT

16 (66.7)
6 (25)
2 (8.3)

31 (75.6)
6 (14.6)
4 (9.8)

37.57 (n:21)
34.71

Disease free survival
(n:58)
(month)
Overall survival

(47.6)
(37.5)
(21.4)
(36.4)

(52.4)
(62.5)
(78.6)
(63.6)

NRAS

Mutation,
n (%)

Wild
n (%)

16 (24.6)

49 (75.4)

0.068

56.12

61.16

0.776

6 (19.4)
10 (29.4)

25 (80.6)
24 (70.6)

6
1
3
6

15
7
11
16

P

0.479

0.236

0.899

0.234
0.484

0.200

0.518

0.177

Mutation
n (%)

Wild
n (%)

12 (18.5)

53 (81.5)

0.182

57.75

60.41

0.343

0.258

9 (29)
3 (8.8)

22 (71)
31 (91.2)

0.037

(71.4)
(87.5)
(78.6)
(72.7)

0.808

5
2
1
4

16
6
13
18

8 (50)
8 (50)

21 (42.9)
28 (57.1)

0.618

8 (66.7)
4 (33.3)

21 (39.6)
32 (60.4)

13 (75.5)
3 (70)
0 (0)

40 (24.5)
7 (30)
2 (100)

8 (15.1)
3 (30)
1 (50)

45 (84.9)
7 (70)
1 (50)

5 (38.5)
4 (23.5)
7 (20)

8 (61.5)
13 (76.5)
28 (80)

3 (23.1)
2 (11.8)
7 (20)

10 (76.9)
15 (88.2)
28 (80)

1.937

1.979

1.25

2.13

0.300

7 (21.2)
1 (9.1)
8 (38.1)

26
10
13

5 (15.2)
3 (27.3)
4 (19.0)

28 (84.8)
8 (72,7)
17 (81.0)

0.666

1
5
3
3
4

(12.5)
(27.8)
(25)
(15.8)
(50)

7
13
9
16
4

(87.5)
(72.2)
(75)
(84.2)
(50)

2
2
3
4
1

(25)
(11.1)
(25)
(21.1)
(12.5)

6
16
9
15
7

(75)
(88.9)
(75)
(78.9)
(87.5)

8
6
2
0

(29.6)
(21.4)
(25)
(0)

19
22
6
2

(70.4)
(78.6)
(75)
(100)

6
3
3
0

(22.2)
(89.3)
(37.5)
(0)

21
25
5
2

(77.8)
(10.7)
(62.5)
(100)

(28.6)
(12.5)
(21.4)
(27.3)

38 (77.6)
9 (18.4)
2 (4.1)

37.45 (n:37) 0.990

36.27
(n:15)

41.00
(n:43)

38.41

40.12

36.04

0.647

0.667

0,416
0.956

(78.8)
(91.9) 0.158
(61,9)

11 (68.8)
3 (18.8)
2 (12.5)

0.459

P

0.366

0.760

(23.8)
(25)
(7.1)
(18.2)

(76.2)
(75)
(92.9)
(71.8)

7 (58.3)
5 (41.7)
0 (0)

42 (79.2)
7 (12.2)
4 (7.5)

0.629

42.00
(n:9)

36.67 (n:49)

0.653

33.16

37.92

0.469

P

0.611
0.084

0.272

0.689

0.829

0.290

0.056
0.652
0.637
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status (P = 0.82 for overall mutation, P = 0.71 for BRAF
mutation and P = 0.30 for NRAS mutation). The duration
of follow-up of the patients ranged between 1 month and
108 months (mean: 36.70). The mean disease-free survival
time was 33.46 months and mean overall survival time was
37.05 months. The mean disease-free survival with BRAF
mutation was slightly shorter than BRAF wild-type (36.27
months), but overall survival was longer (40.12 months).
The results were not significant statistically (P = 0.63, P
= 0.65, consequently). Interestingly, the mean disease-free
survival with NRAS mutation was slightly longer than
NRAS wild-type (42.00 months), but the overall survival
was shorter (33.16 months) and the results were not
significant statistically (P = 0.65, P = 0.63 consequently). A
total of 47 patients (72.3%) did not take adjuvant therapy,
11 patients (16.9%) received chemotherapy (CT), and 4
patients (6.2%) received CT and radiotherapy (RT).
We did not find a statistically significant relationship
between tumor thickness and the number of mitoses or the
presence of mutations in our study. M/F ratio was 1/1 for
overall mutations. Through the evaluation of histological
subtypes, mutations were most commonly seen with ALM
and SSM (62.5% and 41.7%, respectively) followed by MIS
(37.5%), LMM (31.6%), and NM (27.8%).
Twenty-four of the patients had mutations. Sixteen
of them had BRAF mutation (24.6%) and 12 of them
had only BRAF mutation (18.4%). The mean age of the
patients with a mutation (56.58 years) was lower than the
patients without mutation (61.87 years) (P = 0.068). Six of
the patients with BRAF mutation were men (37.5%) and
10 were women (62.5%). Seven of the tumors with BRAF
mutation were located on the head and neck (43.7%), 8
of them were located on extremities (50%), and one was
located on trunk (17.3%). The BRAF mutation was more
common in melanomas with extremity localization but
there was no statistical difference.
Twelve of the patients had NRAS mutation (24.6%)
and 8 of them had only NRAS mutation (18.4%). Nine of
the patients with NRAS mutation were men (75%) and 3
were women (25%); in other words, NRAS mutation was
statistically more common in men (P = 0.036). Five of the
tumors with NRAS mutation were located on the head and
neck (41.7%), 3 of the tumors were located on extremities
(27.3%), and one was located on the trunk (19%). The NRAS
mutation was more common in melanomas with head and
neck localization but there was no statistical difference.
Although there were no significant statistical differences,
67% of the tumors with NRAS mutation had ulceration (P
= 0.08). The NRAS mutation was more common in LMM
cases but there was no significant difference. Five of the
patients with NRAS mutation (41.7%) had CT as adjuvant
therapy and this was statistically insignificant (P = 0.056)
(Table).

976

4. Discussion
Malignant melanoma of the skin is mainly caused by UV
exposure (chronic or intermittent), which is proved by
characteristic base changes in the DNA (C > T transition)
of the melanoma (8). Certainly, the most sensitive
human oncogene for UV is BRAF and is most frequently
mutated in melanoma. The second most frequently UVmutated oncogene is NRAS. These mutations can be
seen with similar rates both in MM and benign tumors
of melanocytes as well. In rarer forms of melanoma,
such as the lentiginous, acral or mucosal forms, the KIT
oncogene is mutated involving several exons, where the
UV-induced alteration is less evident (9).
Different mutation rates for various mutations in
melanoma studies have been reported ranging between
45% and 75% (10,11). One of the studies, conducted in
a common region of our study, reported the overall
mutation rate as 64.2% and most of them were BRAF
and NRAS mutations (12). The other study from Turkey
reported 55.3% as the overall mutation rate. BRAF
and NRAS mutation rates were (29.8%) and (21.3%),
consequently (2). The overall mutation rate was lower in
our study (36.9%).
BRAF mutations in primary melanomas are seen at
a rate of 22%–72% and are mostly frequent in SSM and
NM (4,12–20). The BRAF mutation rate in our study was
15.8% and it was lower than both of these reports (2,12).
As reported before, the BRAF mutation rate in LMM
in Australia and Europe/United States data varies between
8.3% and 27.7% (3,14,21). In the literature, there are so
many studies that have reported BRAF mutations are less
common in melanomas with chronic sun damaged skin
and have higher mutation rate in cases with non ALM
(3,12,14,21). Differently, we found 50% of the ALM cases
were BRAF mutant with extremity localization. This
result should be another evidence showing that BRAF
mutations are more likely to develop in tumors located
on skin subject to intermittent sun exposure (22). Also,
mutation rate was 62.5% in ALM group, but it was not
significant statistically.
NRAS mutations are more commonly found in tumors
on the skin subject to continuous sun exposure (13,23).
Our data was compatible with literature and regional
data (2,12,13,23,24). The mean age of the NRAS mutant
patients was higher than the patients without a mutation
in many reports (2,12,13,20,25). However, in our study,
the mean age of the patients with mutation was slightly
lower than without mutation, but it was not significant.
Most of the patients with mutation were men in our
study. NRAS mutations have been reported to develop
more commonly in NM cases than in other melanoma
subtypes (13,24). However, Wu et al. and Akslen et al. had
reported the NRAS mutation at a similar rate in NM and

EVRENOS et al. / Turk J Med Sci
SSM (15,25). Similarly, we found the rate of mutation in
SSM as 25% and 21.1% in LMM. The absence of ulceration
with NRAS mutation was correlated in a previous study
(26). We found a high incidence of ulceration with NRAS
mutation unlike wild-type but it was not statistically
significant (P = 0.084). Yaman et al. reported similar
findings as in our study (12).
TIL grade was scored as absent, nonbrisk, or brisk
using a previously defined grading system in our study
(27). Tumor-infiltrating lymphocyte grade was evaluated
with melanoma specific survival and with BRAF and
NRAS mutation status before (11,24,25). Edlundh-Rose et
al. found high TIL in BRAF mutant patients relative to
wild-type according to different TIL scale (13). Thomas et
al. found low TIL in NRAS mutant patients (26). Greater
than half of our patients with or without mutation had
no TIL and statistically, there was no correlation between
TIL grade and mutation status.
The necessity of adjuvant CT was statistically
correlated with the presence of NRAS mutation weakly.
Five of the patients with NRAS mutation had adjuvant CT
and 3 of them were stage 2C according to histopathological
staging. Although CT regimen information was not
available, the follow-up period of NRAS mutated patients
ended before recent approvals of new systemic agents that
alter the natural course of the disease.
Stage of the disease at the diagnosis and the BRAF
and/or NRAS mutation status were evaluated in the
literature. Also, the overall and disease-free survival
times with mutant, wild types and prognostic value were
investigated. Previous studies on the associations between
BRAF and NRAS mutations and survival of melanoma
patients have been inconsistent. (11,23,28–33). In our
study, all data items were available for the classification
describing the state of the primary tumor in the AJCC
TNM (tumor, regional nodes, distant metastasis) clinical
melanoma staging system (34). The survival time was
accumulated from the diagnosis date until the date of
death due to melanoma or the end of follow up. In our

study, 83% of the mutations were observed in clinically
nonmetastatic patients at diagnosis. There was no
significant difference between clinical stage and presence
of mutation or mutation type. Also, we found that the
overall survival was slightly shorter than disease-free
survival among the NRAS mutant patients and overall
survival was slightly longer than disease-free survival
among the BRAF mutant patients but this data was not
statistically significant. This may suggest NRAS mutant
advanced clinical stage patients have shorter survival
time.
Lymph node in the body region to which a malignant
tumor first drains is named as sentinel lymph node (SLN).
The importance of SLN sampling in identification of the
occult lymph node metastases has been established, and
accepted as a prognostic factor (35). A limitation of this
study is that we could not evaluate SLN status due to the
few numbers of patient populations with SLN biopsy
indication. So, we could not determine whether NRAS/
BRAF status provides information beyond SLN status for
outcome prediction. We also did not obtain information
regarding definitive chemotherapies potentially utilized,
such as, systemic interferon, or clinical trial participation,
which could confound our results. Although our study
population is similar to the regional data, the larger
population should give more definitive information about
the prognostic value of mutations. So, our data showed
lower mutation rates than in other regional studies.
In conclusion, we found lower mutation rate when
compared to other regional studies. The overall mutation
was seen at younger ages. Tumor mitotic rate was
higher when the tumor was deeper. NRAS mutation
was common in men and NRAS mutant patient needed
more adjuvant CT than the one with the wild type after
therapeutic surgery.
This is the first study from our region evaluating the
prognostic value of clinical stage and necessity of adjuvant
treatment according to the presence of BRAF and NRAS
mutations.
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